Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CB-012 |
Trade Name | |
Synonyms | |
Drug Descriptions |
CB-012 are allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CLEC12A (CLL-1) and genomically edited to resist rejection and immunosuppression, potentially leading to enhanced CLL1-dependent cytotoxicity (Cancer Res (2023) 83 (7_Supplement): 3201). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CB-012 | CB-012 | 0 | 1 |